Michael Hanna

Dr. Hanna is a cardiologist, electrophysiologist and clinical trialist with extensive experience in thrombosis, anticoagulation, heart failure, antiarrythmic drugs and medical devices. As the clinical lead on Bristol-Myers Squibb’s Eliquis program, he directed the phase 3 effort through multiple indications (60,000 patients) leading to approval of the drug by the FDA in 2012. Dr. Hanna received an MD from the University of Connecticut and completed his residency and postdoctoral work at Columbia. Following residency, Dr. Hanna was Director of the EP fellowship program and EP lab director at Presbyterian and Pennsylvania Hospitals.